Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pneumonia I: Introduction01:29

Pneumonia I: Introduction

Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...
Pneumonia I: Introduction01:30

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Atypical Pneumonia01:14

Atypical Pneumonia

Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease include...
Pneumonia II: Pathophysiology01:29

Pneumonia II: Pathophysiology

The pathophysiology of pneumonia involves the following steps:
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Risk factors associated with nausea and vomiting in children with cancer receiving chemotherapy.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners·2022
Same author

Challenges in conducting paediatric trials with off-patent drugs.

Contemporary clinical trials communications·2021
Same author

Shift in bacterial etiology from the CAPNETZ cohort in patients with community-acquired pneumonia: data over more than a decade.

Infection·2021
Same author

[Community-acquired pneumonia].

Der Pneumologe·2020
Same author

Higher chlorzoxazone clearance in obese children compared with nonobese peers.

British journal of clinical pharmacology·2018
Same author

[Epidemiology, Diagnosis and Treatment of Adult Patients with Nosocomial Pneumonia - Update 2017 - S3 Guideline of the German Society for Anaesthesiology and Intensive Care Medicine, the German Society for Infectious Diseases, the German Society for Hygiene and Microbiology, the German Respiratory Society and the Paul-Ehrlich-Society for Chemotherapy, the German Radiological Society and the Society for Virology].

Pneumologie (Stuttgart, Germany)·2018
Same journal

Der Internist·2024
Same journal

Der Internist·2024
Same journal

Der Internist·2024
Same journal

Der Internist·2024
Same journal

Der Internist·2024
Same journal

Der Internist·2024
See all related articles

Related Experiment Video

Updated: May 30, 2026

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
11:32

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

[Community-acquired pneumonia].

K Dalhoff1

  • 1Med. Klinik III, UKSH Campus Lübeck, Deutschland. Klaus.dalhoff@uk-sh.de

Der Internist
|August 13, 2011
PubMed
Summary
This summary is machine-generated.

Community-acquired pneumonia (CAP) is a common severe infection, especially in the elderly. Risk scores like CRB-65 aid in assessing severity, guiding treatment, and prevention strategies for better patient outcomes.

More Related Videos

Experimental Model to Evaluate Resolution of Pneumonia
09:49

Experimental Model to Evaluate Resolution of Pneumonia

Published on: February 17, 2023

Related Experiment Videos

Last Updated: May 30, 2026

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
11:32

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

Experimental Model to Evaluate Resolution of Pneumonia
09:49

Experimental Model to Evaluate Resolution of Pneumonia

Published on: February 17, 2023

Area of Science:

  • Infectious Diseases
  • Pulmonology
  • Geriatrics

Context:

  • Community-acquired pneumonia (CAP) represents a significant public health challenge, being the most frequent severe infectious disease in developed nations.
  • Elderly patients face a particularly high mortality rate from CAP, necessitating effective risk stratification and management strategies.

Purpose:

  • To provide an overview of community-acquired pneumonia (CAP), including its epidemiology, common pathogens, diagnostic approaches, and management guidelines.
  • To emphasize the importance of risk stratification tools, such as the CRB-65 score, in clinical practice for CAP patients.

Summary:

  • CAP diagnosis is supported by clinical symptoms, chest X-rays, and biomarkers, though microbiological investigations are often unnecessary in routine practice.
  • The CRB-65 score (confusion, respiratory rate, blood pressure, age over 65 years) is a recommended tool for risk stratification in CAP.
  • Treatment should align with national guidelines, considering potential differential diagnoses in cases of uncharacteristic symptoms or treatment failure. Prevention through general measures and vaccinations is crucial.

Impact:

  • Facilitates appropriate risk stratification and management of CAP, potentially reducing mortality, especially in vulnerable elderly populations.
  • Highlights the current understanding of CAP pathogens and the limited role of antimicrobial resistance in Germany.
  • Promotes adherence to evidence-based treatment and prevention strategies for community-acquired pneumonia.